EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice

Hilliard L Kutscher, Maria Tamblin, Patrick Kenney iD, Jessica L Reynolds iD

Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)

DOI: 10.1128/aac.00281-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Hilliard L Kutscher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at…. Hauptthemen laut MEDLINE: Chitosan, Mycobacterium tuberculosis, Nanoparticles, beta-Glucans. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolonged daily tuberculosis therapy contributes to toxicity, poor adherence, and drug resistance. We developed rifampin (RIF)-loaded β-glucan-chitosan-poly (lactic co-glycolic) acid nanoparticles (β-C-P nanoparticles) for weekly pulmonary delivery and evaluated a hybrid dosing regimen in a BALB/c Mycobacterium tuberculosis model. Weekly instilled RIF loaded 20% β-C-P nanoparticles combined with daily oral isoniazid (INH) and pyrazinamide (PZA) reduced lung and spleen bacterial burdens comparable to oral daily standard of care (RIF, INH, PZA) and were well tolerated, demonstrating preserved efficacy with reduced RIF dosing frequency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanMycobacterium tuberculosisNanoparticlesbeta-GlucansAntitubercular AgentsAnimalsMice, Inbred BALB CRifampinMiceAdministration, OralPolylactic Acid-Polyglycolic Acid CopolymerIsoniazidLungPyrazinamideFemale

Stichwörter der Autor:innen

Mycobacterium tuberculosisPLGAisoniazidnanoparticlespyrazinamiderifampintuberculosisβ-glucan

Substanzen

Chitosanbeta-GlucansRifampinPolylactic Acid-Polyglycolic Acid CopolymerIsoniazidPyrazinamideAntitubercular Agents

Autor:innen und Institutionen

  • Division of Allergy, Immunology, and Rheumatology Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Institute for Lasers, Photonics and Biophotonics, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Department of Anesthesiology, The State University of New York at Buffalo, Buffalo, New York, USA.
  • Adult and Pediatric Infectious Disease, The State University of New York at Buffalo, Buffalo, New York, USA.

ORCID-Profile: Patrick Kenney, Jessica L Reynolds

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Kutscher, H. L., Tamblin, M., Kenney, P., & Reynolds, J. L. (2026). Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.00281-26

Vancouver

Kutscher HL, Tamblin M, Kenney P, Reynolds JL. Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.00281-26

BibTeX
@article{Kutscher2026,
  author = {Kutscher, Hilliard L and Tamblin, Maria and Kenney, Patrick and Reynolds, Jessica L},
  title = {Weekly pulmonary delivery of β-glucan-chitosan-poly(lactic co-glycolic) acid (β-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {6},
  doi = {10.1128/aac.00281-26}
}
Kostenlos starten →